Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Smith Thesis/COVID Trial Support Early Viral Brilacidin Use

[Last 3 sentences page 35] Brilacidin showed the greatest level of inhibition with direct viral treatment alone or in conjunction with the pre and post treatment. The data from the direct viral treatment indicates Brilacidin in [is] most effective in the early steps [stages] of viral replication. Brilacidin is a strong anti-viral candidate to be further developed and explored as a therapeutic against VEEV.

http://ebot.gmu.edu/bitstream/handle/1920/13025/Smith_thesis_2021.pdf?sequence=1&isAllowed=y

If a patient started study treatment within fewer than 7 days of onset of COVID-19 symptoms, patients in the Brilacidin 5-dose group achieved sustained recovery more quickly compared to the pooled placebo group (p=0.03). For this patient population, early treatment with Brilacidin from onset of symptoms appeared to have a potential positive impact on time to sustained recovery (the study’s primary endpoint), suggesting cases that can be treated close to initial onset of disease may be an attractive population to target for Brilacidin treatment.

http://www.ipharminc.com/press-release/2022/3/7/innovation-pharmaceuticals-reports-additional-findings-based-on-review-of-brilacidin-phase-2-covid-19-trial-results-and-compassionate-use-cases